Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Eli Lilly And Co (LLY) vs ON Holding AG (ONON) Price & Performance

Eli Lilly And CoTrade
ON Holding AGTrade

Price performance (Past 24H)

Key statistics

Eli Lilly And Co vs ON Holding AG — how do they compare? Eli Lilly And Co trades at $1,220.99 (market cap $1.08T), while ON Holding AG trades at $31.07 (market cap $10.33B). The key difference: Eli Lilly And Co is far larger — about 104.5× ON Holding AG's market cap, and Eli Lilly And Co pays a 0.57% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.

LLYONON
Market Cap
$1.08T$10.33B
Sector
HealthTechnology
52-Week High
$1.24K$50.63
52-Week Low
$639.43$30.91
Enterprise Value
$1.13T$9.47B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

ON Holding AG

ONON stock is trading at $31.01, down 20.04% after Q2 2026 results showed a revenue miss and lowered full-year growth guidance. The technical picture is bearish with support near $29, while fundamentals reveal strong profitability margins and earnings beats. Analyst sentiment remains largely positive despite the sell-off, with a consensus price target of $52.86.

The outlook is mixed: robust DTC growth and margin expansion offer upside, but wholesale softness and guidance cuts pose near-term risks. Investors face volatility from consumer spending concerns and competitive pressures, though long-term brand momentum supports a growth-at-a-reasonable-price thesis.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY

About ON Holding AG

ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.

Read more on ONON